Profile data is unavailable for this security.
About the company
Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.
- Revenue in USD (TTM)2.85m
- Net income in USD93.35m
- Incorporated1998
- Employees7.00
- LocationTraws Pharma Inc12 Penns TrailNEWTOWN 18940United StatesUSA
- Phone+1 (267) 759-3680
- Fax+1 (302) 636-5454
- Websitehttps://www.trawspharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allarity Therapeutics Inc | 0.00 | -15.31m | 13.59m | 6.00 | -- | 1.13 | -- | -- | -2.31 | -2.31 | 0.00 | 0.7455 | 0.00 | -- | -- | 0.00 | -74.37 | -62.78 | -122.61 | -113.20 | -- | -- | -- | -- | -- | -- | 0.1037 | -- | -- | -- | -23.21 | -- | 106.17 | -- |
| Apimeds Pharmaceuticals US Inc | 0.00 | -5.16m | 13.83m | 2.00 | -- | 1.70 | -- | -- | -0.4762 | -0.4762 | 0.00 | 0.6489 | 0.00 | -- | -- | 0.00 | -111.07 | -- | -138.71 | -- | -- | -- | -- | -- | -- | -162.30 | 0.0577 | -- | -- | -- | -78.73 | -- | -- | -- |
| Curis Inc | 11.65m | -36.56m | 13.96m | 33.00 | -- | -- | -- | 1.20 | -3.68 | -3.68 | 1.05 | -1.15 | 0.3323 | -- | 3.75 | 353,030.30 | -104.28 | -37.70 | -259.56 | -42.63 | 99.47 | 96.89 | -313.79 | -423.79 | -- | -- | -- | -- | 8.83 | 1.75 | 8.49 | -- | -- | -- |
| P3 Health Partners Inc | 1.44bn | -131.05m | 14.48m | 360.00 | -- | -- | -- | 0.01 | -40.18 | -40.18 | 442.85 | -5.72 | 1.91 | -- | 14.07 | 4,013,756.00 | -37.78 | -49.89 | -113.11 | -253.77 | -4.05 | -1.15 | -19.83 | -46.73 | -- | -5.36 | 0.9304 | -- | 18.48 | 59.38 | -135.14 | -- | -- | -- |
| Vyome Holdings Inc | 4.19m | -11.35m | 14.73m | 17.00 | -- | 5.73 | -- | 3.51 | -182.98 | -182.98 | 5.45 | 0.4553 | 0.6626 | -- | 6.14 | 246,742.90 | -181.86 | -143.74 | -557.79 | -202.53 | 62.39 | 61.09 | -274.45 | -325.23 | -- | -- | 0.00 | -- | -7.74 | 19.53 | 37.38 | -- | -- | -- |
| NuCana PLC (ADR) | 0.00 | -37.48m | 14.91m | 20.00 | -- | 0.4224 | -- | -- | -7,197.40 | -7,197.40 | 0.00 | 4.92 | 0.00 | -- | -- | 0.00 | -106.16 | -47.75 | -180.13 | -58.87 | -- | -- | -- | -- | -- | -1.59 | 0.0052 | -- | -- | -- | 31.25 | -- | -25.32 | -- |
| Traws Pharma Inc | 2.85m | 93.35m | 15.34m | 7.00 | 0.068 | 3.01 | -- | 5.39 | 28.24 | 28.24 | 0.4566 | 0.6373 | 0.2662 | -- | 1.38 | 406,571.40 | -124.51 | -151.85 | -517.46 | -207.35 | -- | -- | -467.64 | -21,652.42 | -- | -- | 0.00 | -- | 0.00 | -36.47 | -188.55 | -- | -- | -- |
| Iterum Therapeutics PLC | 390.00k | -26.96m | 15.54m | 9.00 | -- | -- | -- | 39.85 | -0.7488 | -0.7488 | 0.0107 | -0.1507 | 0.0161 | -- | 0.9512 | 43,333.33 | -111.35 | -99.44 | -231.48 | -169.64 | 94.87 | -- | -6,913.08 | -- | 1.96 | -3.43 | 1.28 | -- | -- | -- | 35.44 | -- | -39.16 | -- |
| Klotho Neurosciences Inc | 0.00 | -11.29m | 16.03m | 3.00 | -- | 1.54 | -- | -- | -0.3264 | -0.3264 | 0.00 | 0.1411 | 0.00 | -- | -- | 0.00 | -180.10 | -- | -197.00 | -- | -- | -- | -- | -- | -- | -1.90 | 0.00 | -- | -- | -- | -556.89 | -- | -- | -- |
| Pasithea Therapeutics Corp | 0.00 | -13.49m | 16.16m | 4.00 | -- | 0.4269 | -- | -- | -5.21 | -5.21 | 0.00 | 1.64 | 0.00 | -- | -- | 0.00 | -83.64 | -- | -89.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.34 | -- | -- | -- |
| Eom Pharmaceutical Holdings Inc | 0.00 | -4.93m | 16.31m | 3.00 | -- | -- | -- | -- | -0.0435 | -0.0435 | 0.00 | -0.0212 | -- | -- | -- | 0.00 | -- | -126.34 | -- | -171.37 | -- | -- | -- | -- | -- | -- | 7.41 | -- | -- | -- | -254.37 | -- | -- | -- |
| Fibrobiologics Inc | 0.00 | -18.50m | 16.36m | 13.00 | -- | 94.98 | -- | -- | -0.4809 | -0.4809 | 0.00 | 0.0026 | 0.00 | -- | -- | 0.00 | -192.59 | -- | -636.43 | -- | -- | -- | -- | -- | -- | -27.09 | 0.9734 | -- | -- | -- | 41.44 | -- | -- | -- |
| Citius Pharmaceuticals Inc | 0.00 | -37.43m | 16.47m | 23.00 | -- | 0.2122 | -- | -- | -3.84 | -3.84 | 0.00 | 3.74 | 0.00 | -- | -- | 0.00 | -32.10 | -29.86 | -52.00 | -35.19 | -- | -- | -- | -- | 0.1257 | -244.30 | 0.0127 | -- | -- | -- | 6.85 | -- | 400.55 | -- |
| Linike Medical Group Ltd | 0.00 | -306.90k | 17.16m | -- | -- | -- | -- | -- | -0.1102 | -0.1102 | 0.00 | -0.153 | 0.00 | -- | -- | -- | -278.62 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -651.26 | -- | -- | -- |
Data as of Feb 12 2026. Currency figures normalised to Traws Pharma Inc's reporting currency: US Dollar USD
15.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Squadron Capital Management LLCas of 30 Sep 2025 | 591.00k | 7.40% |
| Adage Capital Management LPas of 30 Sep 2025 | 330.00k | 4.13% |
| Vestal Point Capital LPas of 30 Sep 2025 | 150.00k | 1.88% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 55.19k | 0.69% |
| Geode Capital Management LLCas of 30 Sep 2025 | 43.44k | 0.54% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 31.80k | 0.40% |
| Ikarian Capital LLCas of 30 Sep 2025 | 28.49k | 0.36% |
| Two Sigma Investments LPas of 30 Sep 2025 | 22.02k | 0.28% |
| HRT Financial LPas of 30 Sep 2025 | 12.57k | 0.16% |
| XTX Markets LLCas of 30 Sep 2025 | 10.71k | 0.13% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
